Clinical Innovation in Urethral Stricture Care
Prezilume Therapy for Selected Short Urethral Strictures
Prezilume Therapy is a mitomycin-C–based balloon approach developed by Dr. Parwez Alam for selected patients with short urethral stricture disease. The aim is to combine controlled urethral dilatation with local anti-fibrotic drug delivery as part of a carefully selected treatment pathway. Suitability depends on the stricture’s location, length, severity, previous treatment and the patient’s overall clinical condition.
Developed by Dr. Parwez Alam
Designed for Selected Short Urethral Strictures
Mitomycin-C–Based Balloon Drug Delivery
Evaluation-Led, Patient-Specific Treatment Planning
Why the Approach Was Developed
What Is Prezilume Therapy?
Prezilume Therapy is the name given by Dr. Parwez Alam to a balloon-based urethral stricture treatment approach that uses mitomycin C as the locally delivered medicine. The concept is intended for selected short urethral strictures, where a minimally invasive endoscopic approach may be clinically appropriate.
Urethral stricture disease occurs when scar tissue narrows the urethra and restricts urinary flow. Treatment depends on several factors, including the site and length of the narrowing, the amount of scar tissue, whether the stricture has recurred, previous procedures and the patient’s bladder function and overall health.
Mitomycin C has anti-fibrotic properties and has been studied as an adjunct in urethral stricture treatment. However, current guideline literature notes uncertainty around dose, technique and standardisation. The Prezilume Therapy page should therefore describe the technique transparently as Dr. Parwez Alam’s clinician-developed approach and should not imply that external guideline evidence directly validates this specific balloon-delivery protocol.
Why the Approach Was Developed
A Clinical Innovation Focused on Access and Stricture Care
The development rationale for Prezilume Therapy included two practical clinical considerations: the challenge of recurrent scar formation in selected short urethral strictures, and the need to explore a more accessible drug-assisted balloon pathway in settings where commercial drug-coated balloon technologies may be difficult for some patients to access.
This rationale should be presented as the treating doctor’s clinical innovation objective rather than as a proven cost-effectiveness or superiority claim. No exact savings, recurrence reduction, success percentage or comparative outcome should be published until the relevant evidence is reviewed and approved for website use.
Who May Be Considered?
Who May Be Considered for Prezilume Therapy?
Prezilume Therapy may be considered for selected patients with a short urethral stricture after detailed urological assessment. The final decision depends on the individual anatomy and clinical history.
Stricture location and measured length
Degree of narrowing and scar tissue
First-time versus recurrent stricture
Previous dilation, DVIU, urethroplasty or other procedures
Urinary flow symptoms and post-void residual urine
Infection status and urine testing when indicated
Overall bladder function and other urological conditions
Patients who may need a different approach
A Structured, Evaluation-Led Treatment Pathway
Consultation & Stricture Assessment
symptoms, previous procedures, reports and clinical history are reviewed.
Diagnostic Confirmation
the narrowing is characterised using appropriate tests and imaging/endoscopy where needed.
Treatment Selection
Prezilume Therapy is considered only if the stricture pattern and clinical situation are appropriate.
Procedure & Local Drug Delivery
treatment is performed in a controlled clinical setting by the urology team; the website should not provide step-by-step procedural instructions.
Follow-Up
urinary symptoms, flow, recurrence risk and any further treatment needs are reviewed according to the clinical plan.
Prezilume Therapy and Optilume: Important Differences
Both names refer to drug-assisted balloon concepts used in the context of urethral stricture care, but they are not the same therapy and should not be presented as interchangeable products.
| Feature | Prezilume Therapy | Optilume |
|---|---|---|
| Technique / Name | Clinician-developed approach named by Dr. Parwez Alam | Commercial urethral drug-coated balloon device |
| Drug Concept | Mitomycin C | Paclitaxel |
| Public Positioning | Selected short urethral strictures after individual evaluation | FDA-approved in the United States for adult males with anterior urethral strictures ≤3 cm, subject to its labeling |
| Evidence Statement | Doctor confirms clinical evidence and formal documentation; specific public outcome data not included until source review | Supported by the ROBUST clinical programme and FDA PMA documentation |
| Comparative Claim | No superiority, equivalence or cost-effectiveness claim should be made without direct comparative evidence | Do not use Optilume evidence as proof of Prezilume outcomes |
Evidence, Safety & Transparency
Clinical Innovation with Transparent Patient Communication
Dr. Parwez Alam confirms that Prezilume Therapy has supporting clinical evidence and that the required formalities have been completed. Because the underlying evidence package has not been supplied for this content review, the public website should initially use descriptive, non-numerical language.
Mitomycin C has been studied as an adjunct to minimally invasive urethral-stricture treatment, but the EAU 2026 guideline notes a lack of standardisation in dose, volume and technique and advises intralesional injections only within a clinical-trial framework. That guideline evidence should be treated as background on mitomycin C in stricture disease, not as direct validation of the specific Prezilume balloon protocol.
Do not publish until evidence is reviewed
✓ Success rate or recurrence percentage ✓Claims of superiority or equivalence to Optilume, DVIU, dilation or urethroplasty ✓ “First in the world”, “first-ever” or patent/invention priority claims ✓ Guaranteed avoidance of recurrence or surgery ✓ Exact cost-saving percentages
May be published now
✓ Technique name: Prezilume Therapy ✓ Developed by Dr. Parwez Alam ✓ Mitomycin-C–based balloon approach ✓ Intended for selected short urethral strictures ✓ Patient selection and follow-up are required
Potential Benefits and Limitations to Discuss
What Patients Should Understand Before Choosing Treatment
The purpose of the consultation is to determine whether a minimally invasive drug-assisted balloon strategy is appropriate compared with observation, dilation, urethrotomy, commercial drug-coated balloon treatment, or urethroplasty. Each option has different evidence, recurrence patterns, risks, recovery considerations and suitability criteria.
Possible patient-centred objectives
✓A minimally invasive treatment pathway in appropriately selected cases ✓Local delivery of an anti-fibrotic medicine as part of the procedure ✓A treatment option developed with access and affordability considerations in mind ✓ Structured follow-up for symptoms, flow and recurrence assessment
Important limitations
✓ Not appropriate for every urethral stricture ✓ Recurrence can occur after any endoscopic stricture treatment ✓ Some patients may still need urethroplasty or another reconstructive procedure ✓ Potential adverse effects, procedural risks and mitomycin-related considerations must be discussed individually
Dr. Parwez Alam: Clinical Innovation & Technique Development
Developed by Dr. Parwez Alam
Prezilume Therapy is a named clinical technique developed by Dr. Parwez Alam as part of his interest in reconstructive urology and urethral stricture disease. His broader clinical focus includes endourology, minimally invasive surgery, urethral reconstruction, functional urology and evidence-based treatment planning.
The website may describe Dr. Parwez Alam as the developer of Prezilume Therapy based on the doctor’s confirmed authorship. Any future statements about invention priority, patents, awards, first use, trial results or comparative outcomes should be tied directly to the supporting record before publication.
Consultation for Urethral Stricture
Discuss the Stricture, Previous Treatment and Available Options
Patients with weak urinary flow, straining, recurrent urinary infections, spraying, incomplete emptying, previous urethral procedures or a known urethral stricture can book an evaluation with Dr. Parwez Alam. The consultation should focus first on confirming the stricture pattern and then comparing the treatment options appropriate to that individual case.
Consultation options
- In-person urethral stricture assessment in Aligarh
- Online report review / second-opinion discussion for appropriate outstation patients
- Pre-visit review of previous RUG/VCUG, cystoscopy, uroflowmetry or operative records where available
- International and outstation consultation pathway when clinically appropriate
Frequently Asked Questions About Urology Services
What is Prezilume Therapy?
Prezilume Therapy is a balloon-based urethral stricture treatment approach developed by Dr. Parwez Alam for selected short strictures. It uses mitomycin C as the locally delivered medicine and is considered only after clinical evaluation.
Who developed Prezilume Therapy?
Dr. Parwez Alam has confirmed authorship and development of the named technique. The website should use this wording without adding unsupported “first in the world” or priority claims.
Is Prezilume Therapy suitable for every urethral stricture?
No. Suitability depends on the location, length, severity and recurrence pattern of the stricture, previous procedures, infection status, bladder function and other clinical factors. Some patients are better treated with urethroplasty or another approach.
How is Prezilume different from Optilume?
Prezilume uses a mitomycin-C–based balloon approach developed by Dr. Parwez Alam, whereas Optilume is a commercial paclitaxel-coated balloon device with its own regulatory labeling and clinical evidence. The two should not be presented as equivalent therapies.
Does Prezilume Therapy guarantee that the stricture will not return?
No. Urethral strictures can recur after different forms of treatment. No website content should promise permanent cure, zero recurrence or guaranteed avoidance of future surgery.
What tests may be needed before treatment?
Depending on the case, evaluation may include history and examination, urine testing, uroflowmetry, post-void residual measurement, urethrography and cystoscopy. The exact work-up is selected by the urologist.
Can I get an online opinion before travelling to Aligarh?
Yes. Selected patients can share previous reports and treatment records for an online review or second-opinion discussion. An in-person examination or further testing may still be required.
Is Prezilume Therapy an established guideline-standard treatment?
The page should not present Prezilume Therapy as an established guideline-standard treatment at this stage. Dr. Parwez Alam confirms supporting clinical evidence and completed formalities, but public evidence details should be added only after the source material is reviewed for publication wording.